Among patients with non-muscle-invasive bladder cancer (NMIBC), neoadjuvant treatment with mitomycin C prior to transurethral ...

Two recent analyses provide new insight into the clinical efficacy of BCG versus chemotherapy with mitomycin C in intermediate-risk and high-risk bladder cancer. BCG immunotherapy showed a ...

In December 2022, the company reported findings from the Phase IIb OPTIMA II trial of UGN-102 (mitomycin) to treat LG-IR-NMIBC. "UroGen begins subject dosing in Phase III bladder cancer drug trial ...